Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Oct 1 · below the Ichimoku cloud · RSI 32 · MACD below its signal
| 2.68 | 52-week high | +109.38% |
| 1.95 | Previous month high | +52.34% |
| 1.57 | Previous month low | +22.27% |
| 1.48 | Previous week high | +15.63% |
| 1.37 | R3 (classic) | +7.16% |
| 1.35 | R2 (classic) | +5.73% |
| 1.34 | Previous day high | +4.30% |
| 1.32 | R1 (classic) | +2.86% |
| 1.30 | Pivot | +1.43% |
| 1.28 | Price now | |
| 1.28 | Previous day low | −0.00% |
| 1.26 | S1 (classic) | −1.43% |
| 1.24 | S2 (classic) | −2.86% |
| 1.22 | Previous week low | −4.69% |
| 1.21 | S3 (classic) | −5.73% |
| 0.8400 | 52-week low | −34.38% |
None of the 29 investors followed here reported a position in ALZN in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ALZN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 25, 2026 | Ault Milton C IiiDirector | Sale at price 1.56 per share. | 2K | $3.12K |
| Apr 13, 2026 | Ault Milton C IiiDirector | Purchase at price 1.00 - 1.03 per share. | 110.4K | $110.97K |
| Apr 13, 2026 | Ault Milton C IiiDirector | Purchase at price 1.00 - 1.03 per share. | 110.4K | $110.97K |
| Apr 13, 2026 | Ault Milton C IiiDirector | Purchase at price 1.00 per share. | 108.4K | $108.90K |
| Dec 22, 2025 | Ault Milton C IiiDirector | Sale at price 2.07 per share. | 1.9K | $3.83K |
| Dec 18, 2025 | Horne William BDirector | Sale at price 2.12 per share. | 3.3K | $7.06K |
| Oct 22, 2025 | Mcgrath Lynne FaheyDirector | Sale at price 2.29 per share. | 30 | $69 |
| Oct 8, 2025 | Ault Milton C IiiDirector | Sale at price 2.32 - 2.44 per share. | 121.8K | $294.55K |
| Oct 7, 2025 | Ault Milton C IiiDirector | Conversion of Exercise of derivative security at price 2.32 per share. | 61.7K | $143.24K |
| Oct 6, 2025 | Ault Milton C IiiDirector | Conversion of Exercise of derivative security at price 2.32 per share. | 200K | $464.00K |
| Oct 6, 2025 | Ault Milton C IiiDirector | Sale at price 2.45 - 2.49 per share. | 139.4K | $344.22K |
| Oct 2, 2025 | Ault Milton C IiiDirector | Sale at price 2.35 - 2.44 per share. | 123.4K | $296.79K |
| Sep 30, 2025 | Ault Milton C IiiDirector | Conversion of Exercise of derivative security at price 2.32 per share. | 100K | $232.00K |
| Sep 29, 2025 | Ault Milton C IiiDirector and Beneficial Owner of more than 10% of a Class of Security | Sale at price 2.31 - 2.33 per share. | 79.6K | $184.16K |
| Sep 24, 2025 | Ault Milton C IiiDirector and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security at price 2.32 per share. | 100K | $232.00K |
| Sep 24, 2025 | Ault Milton C IiiDirector and Beneficial Owner of more than 10% of a Class of Security | Sale at price 2.31 - 2.38 per share. | 97K | $226.92K |
| Sep 21, 2025 | Ault Milton C IiiDirector and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security at price 2.32 per share. | 100K | $232.00K |
| Sep 18, 2025 | Ault Milton C IiiDirector and Beneficial Owner of more than 10% of a Class of Security | Sale at price 2.35 per share. | 77K | $180.86K |
| Sep 17, 2025 | Ault Milton C IiiDirector and Beneficial Owner of more than 10% of a Class of Security | Sale at price 2.45 - 2.47 per share. | 23K | $56.70K |
| Sep 16, 2025 | Ault Milton C IiiDirector and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security at price 2.32 per share. | 100K | $232.00K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 18.1 | -6.5 | -47.3 | 7.5 | 4.4 | 0.8 | 9.2 | 22.1 | 8.1 | -26.0 | −29.7% | ||
| 2025 | -2.2 | -27.8 | 15.6 | -30.4 | -35.5 | -24.0 | -22.7 | 8.4 | -2.5 | 6.3 | -13.4 | -16.9 | −82.6% |
| 2024 | -3.4 | 6.5 | 9.2 | -28.9 | -17.0 | -33.2 | -9.4 | -34.2 | -28.1 | -7.1 | -17.2 | -10.8 | −87.0% |
| 2023 | 17.5 | -19.1 | -20.9 | 28.7 | 32.7 | -29.8 | -11.2 | -42.2 | -9.5 | -50.7 | -30.9 | -26.4 | −89.5% |
| 2022 | -19.5 | -22.9 | 4.2 | -17.1 | -7.6 | -8.3 | 2.9 | 1.8 | 31.5 | -1.7 | -1.7 | -50.9 | −70.3% |
| 2021 | -49.4 | -30.8 | 0.7 | -30.5 | 0.0 | -11.2 | −78.3% |
Buy / hold / sell counts
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.